The Use of Glofitamab in Relapsed Diffuse Large B-Cell Lymphoma

[11] CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-CellEngaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [J]. BLOOD, 2022, 140 : 9461 - 9463

[12] ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (04) : 625 - 638

[13] Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL) [J]. BLOOD, 2021, 138

[14] Padala S.A., 2023, StatPearls

[15] Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy [J]. BLOOD, 2021, 138

[16] Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy [J]. CANCERS, 2022, 14 (10)

[17] Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (12) : 2238 - +

[18] Topp MS., 2023, Blood, V142, P3085

[11] CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-CellEngaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [J]. BLOOD, 2022, 140 : 9461 - 9463

[12] ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (04) : 625 - 638

[13] Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL) [J]. BLOOD, 2021, 138

[14] Padala S.A., 2023, StatPearls

[15] Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy [J]. BLOOD, 2021, 138

[16] Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy [J]. CANCERS, 2022, 14 (10)

[17] Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (12) : 2238 - +

[18] Topp MS., 2023, Blood, V142, P3085